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Introduction
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most common fatal cancer worldwide [1] . Liver has many unique metabolic functions including gluconeogenesis, glycogen synthesis and storage, as well as blood glucose homeostasis. As HCC is highly proliferative, altered metabolic mechanisms are required to support its rapid demand for nutrients. Better understanding of the metabolic machinery of HCC is fundamental to devising better therapeutic strategies against HCC.
Normal differentiated cells metabolize glucose through oxidative phosphorylation in the presence of oxygen and through glycolysis in the absence of oxygen. Contrarily, despite a less energy-efficient metabolic route, cancer cells metabolize glucose through glycolysis even in the presence of oxygen and the phenomenon is called the Warburg Effect [2] . Increase of glucose uptake and production of lactate are typical signatures of the Warburg Effect [2] . Accumulating studies have shown that this preferential metabolic reprogramming to glycolysis channels glucose intermediates for the maximal biomolecule and anti-oxidant production [3] .
Pyruvate kinases (PKs) are located at the pivotal position of glycolysis and catalyze the last step of glycolysis in which the phosphate group from phosphoenolypyruvate (PEP) is transferred to ADP, producing pyruvate and ATP. Pyruvate kinases (PKs) include 4 isoforms encoded by 2 paralogous genes, the PKL and PKM genes. The PKL gene generates PKL and PKR isoforms that are driven by different tissue-specific promoters [4] . The PKM gene is alternatively spliced by mutual exclusion of the 10 th and 9 th exons to generate PKM1 and PKM2, respectively [5] . PKL is abundantly expressed in normal liver and kidney; PKR is abundantly expressed in red blood cells; PKM1 is abundantly expressed in adult muscle, brain, bladder, and fibroblasts, whereas PKM2 is abundantly expressed in tissues during embryogenesis. PKM2 is also the predominant form that is over-expressed in multiple cancers including lung [6] , colorectal [7] , and gastric cancer [8] . Furthermore, PKM2 over-expression has been suggested to be associated with advanced stage and lymph node metastasis in colorectal cancer and associated with poor prognosis in gastric cancer [8] . Studies have shown that PKM2 is less glycolytically active than PKM1 [6, 9] , therefore allowing the channeling of glucose intermediates upstream of pyruvates for antioxidant (NADPH), fatty acid, and nucleotide production [3] . Replacement of PKM2 by other PK isoform in lung cancer cell line markedly decreased glycolytic activity and suppressed tumor growth [6] .
We herein report that PKM2, but not other PK isoforms, was over-expressed in human HCCs and its over-expression was associated with aggressive clinicopathological features and poor prognosis. Stable knockdown of PKM2 in multiple HCC cell lines decreased glucose uptake and lactate accumulation. Stable knockdown of PKM2 increased intracellular reactive oxygen species (ROS) level, which has been shown to be detrimental to cancer cells [10] . In addition, stable knockdown of PKM2 hampered HCC proliferation in vitro and tumorigenicity and metastasis in vivo. Intriguingly, we showed that PKM2 expression was regulated by the most abundant microRNA in the liver, miR-122. We found that miR-122 interacted with the 3UTR of PKM2 and suppressed PKM2 expression in human HCCs. Re-expression of miR-122 in HCC cell lines also decreased glucose uptake and lactate accumulation. Importantly, expression levels of PKM2 and miR-122 inversely correlated in human HCCs and non-tumorous liver tissues. Our results have revealed that the miR-122-mediated switch of PK isoforms drove HCC metabolic reprogramming. Establishment of PKM2 knockdown and miR-122 over-expressing HCC cells pLKO.1 plasmid carrying shRNA sequences against PKM2 (shPKM2-88: NM_182471.1-1070s1c1, shPKM2-94: NM_182471.1-1736s1c1), PKL (shPKL-39: NM_000298.4-1376s1c1, shPKL-94: NM_000298.4-221s1c1) and non-target control (NTC) were purchased from Sigma (St Louis, MO). pMIRNA1 plasmid carrying miR-122 precursor sequences was purchased from System Biosciences (Mountain View, CA). To generate HCC cells that stably express -NTC andshPKM2 or -EV and -miR-122 precursor sequences, pLKO/pMIRNA1 plasmids and viral packaging plasmids (System Biosciences) were transfected into 293FT packaging cells. Viral particles were collected and infected into parental HCC cells with polybrene (Sigma). Puromycin was used to select stable transfectants.
Materials and Methods

Patient samples and cell lines
Luciferase reporter assay and transfection of miR-RNA precursors and locked nucleic acids (LNAs)
Wild-type and mutated 3UTR of PKM2 were inserted into pmirGLO Dualluciferase miRNA target expression vector (Promega, Madison, WI). Sensor sequences, perfectly complementary to the miR-122, were included as positive control. A day after these constructs were transiently transfected into BEL-7402 cells by Lipofectamine 2000 (Life Technologies, Grand Island, NY), 5 pmol of miR-122 precursors (Life Technologies) were transfected by X-tremeGENE DNA transfection reagent (Roche). A day later, luciferase signals were quantitated by Dual-LuciferaseReporter Assay based on manufacturer's protocol (Promega). LNA Ctrl (control) and LNA miR-122 were purchased from Exiqon and were transfected by X-tremeGEME DNA transfection reagent in PLC/PRF/5 cells based upon manufacturer's protocol.
Real-time quantitative PCR
Trizol Reagent (Life Technologies) was used to extract total RNA. cDNA synthesis was performed by reverse transcription kit (Life Technologies). SYBR Green PCR Master Mix (Life Technologies) and primers specific to PKL, PKR, PKM1, and PKM2 (S1 Table) were used for real-time quantitative PCR (RT-qPCR).
Clinicopathological correlation and patients' survival analysis
The clinicopathological features of HCC patients were analyzed by pathologist (Irene Oi-Lin Ng), as we previously described [11] . The parameters consisted of tumor size, venous invasion, tumor microsatellite formation, tumor encapsulation, cellular differentiation by Edmondson grading, direct liver invasion, background liver disease, and pTNM tumor stage. These features were correlated with PKM2 mRNA expression by Mann Whitney test. Tumor recurrence rate was calculated from the date of resection to the date when recurrence was first detected or, in the absence of tumor, to one year after resection. Overall survival was calculated from the date of resection to the date of death or five years after resection. The prognostic significance of PKM2 overexpression (T/NT2 fold) was determined by the Kaplan-Meier method followed by the log-rank test. All statistical tests were performed with SPSS20.0 and considered significant when the P-values were less than 0.05.
Animal studies
All protocols for animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research, the University of Hong Kong and followed under the Animals (Control of Experiments) Ordinance of Hong Kong. For subcutaneous injections in nude mice, 1610 6 MHCC-97L or SMMC-7721 cells were injected into the right flanks of 6-8 weeks old male BALB/c NUDE mice. Three dimensions of tumors were measured by caliper every week. Tumor volume was calculated by the following equation: width (mm) 6 length (mm) 6 depth (mm)60.52 [12, 13] . Tumor volume of each group was plotted against time and compared to the corresponding controls. Mice were sacrificed 4 weeks after the subcutaneous injection. Tumors were harvested and weighed. For orthotopic liver tumor implantation in nude mice, 1610 6 luciferase-labeled MHCC-97L cells were injected into the left lobes of the livers of 6-8 week-old nude mice. Six weeks after implantation, mice were administered with 100 mg/kg D-luciferin 5 minutes before bioluminescent imaging (IVIS   TM   100 Imaging System, Xenogen, Hopkinton, MA). Lungs were harvested for ex-vivo imaging and histological analysis. Livers were harvested and three dimensions of tumors were measured for tumor volume calculation.
Lactate, glucose uptake, reactive oxygen species (ROS), and NADPH measurement 
Results
Expression of PK isoforms in human HCC
To study the expression of different forms of the PK family, we designed RTqPCR primers that were specific to individual isoforms and assessed their expression in 60 cases of human HCC samples and their corresponding nontumorous liver tissues (NT). Interestingly, we found that only PKM2 was overexpressed in the human HCCs while PKM1 and PKL expression levels remained unchanged (Fig. 1A) . PKR expression was undetectable in both HCC and NT tissues (data not shown). Notably, PKL was the predominant form in the NT livers but its expression was unchanged in HCC tissues, implying that PKL might contribute to the normal metabolic functions in the livers while PKM2 might contribute to metabolic functions in HCC. At the mRNA level, PKM2 was (E) Over-expression of PKM2 in human HCC was associated with poor prognosis. HCC patients were categorized into two groups: PKM2 over-expression and PKM2 normal/under-expression. PKM2 was considered to be over-expressed when HCC/NT2 folds and was considered to be normal/under-expressed otherwise. HCC patients with PKM2 over-expression had a higher 1-year tumor recurrence rate after surgical resection than HCC patients without PKM2 over-expression, 46.667% Vs 25%. (F) Patients with PKM2 over-expression had lower 5-year overall survival rates after surgical resection. P values were calculated by Kaplan-Meir log rank test. up-regulated by at least two-fold in 29 (48.33%) of the 60 human HCC samples (Fig. 1B) . To further examine the PKM2 protein expression, we performed immunohistochemistry (IHC) study with an antibody against PKM2 on the tissue microarray slides containing tissue cores from 109 HCCs and their corresponding NT livers. We found that PKM2 was over-expressed in 68.8% (75/109) of the HCC patients (Fig. 1C) . In line with mRNA expression study, PKL protein was not altered in human HCCs (S1 Fig.) .
Clinicopathological correlation and prognostication of PKM2 in human HCCs
Over-expression of PKM2 in HCC tumors was significantly associated with aggressive pathological features including tumor microsatellite formation (P50.033), venous invasion (P50.035), and absence of tumor encapsulation (P50.032) (Fig. 1D ). More importantly, HCC patients with PKM2 overexpression have higher 1-year recurrence rate than HCC patients without PKM2 over-expression (46.667% versus 25%) (Fig. 1E) . Furthermore, over-expression of PKM2 was associated with shorter overall survival (P50.043) in HCC patients (Fig. 1F ).
PKM2 and HCC metabolism
To study the functional implications of PKM2, we employed short-hairpin RNA (shRNA) approach to stably knockdown PKM2 in multiple HCC cell lines such as SMMC-7721 and MHCC-97L, that expressed a high level of PKM2 ( Fig. 2A) . Theoretically, these shRNA sequences could not distinguish PKM2 and PKM1 isoforms. However, we found these sequences only affected PKM2 but not PKM1. This may be due to the basically low expression of PKM1 in these HCC cell lines. PKM1 was only barely detected at the same exposure time when PKM2 was already easily detected (S2A Fig.) . The mRNA expression values of PKM2 and PKM1 in human HCC samples and cell lines also reflected that the expression of PKM1 was much lower than PKM2 in HCC (Fig. 1A, S2B Fig.) . Different shRNA knockdown sequences of PKM2 but not PKL consistently suppressed HCC cell proliferation when compared to the non-target control (NTC) shRNA (Fig. 2B  and S3 Fig.) . To investigate whether PKM2 induced the Warburg effect in HCC cells, we assessed lactate accumulation and glucose uptake rate in the -NTC andshPKM2 HCC cells under aerobic conditions. Knockdown of PKM2 consistently suppressed lactate accumulation (Fig. 2C ) and glucose uptake rate (using both colorimetric assay and 2-NBDG staining) in multiple HCC cell lines (Fig. 2D and  2E ). In addition, knockdown of PKM2 substantially induced intracellular ROS level in multiple HCC cell lines (Fig. 2F) . Increase of ROS might be caused by a reduction of NADPH. In line with our postulation, we found that knockdown of PKM2 decreased the NADPH level in SMMC-7721 cells (Fig. 2G) . Knockdown of PKM2 suppressed tumor growth and metastasis in vivo
To evaluate the effect of PKM2 in HCC growth in vivo, we subcutaneously injected SMMC-7721-and MHCC-97L-NTC and -shPKM2 cells into nude mice and found that knockdown of PKM2 drastically hampered tumor growth (Fig. 3A  and 3B) . Furthermore, to better mimic the tumor microenvironment of human HCC, we orthotopically injected luciferase-labeled MHCC-97L-NTC and -shPKM2 cells into the left lobes of the livers of nude mice. Knockdown of PKM2 not only suppressed tumor growth in the livers (Fig. 3C) but also suppressed the growth of metastatic lesions found in the lungs as shown by the Xenogen imaging and expression of human genes HK2 in the mouse lung tissues (5/5 mice in NTC vs 3/5 mice in shPKM2) (Fig. 3D ).
PKM2 regulation in human HCC
Next, we investigated the mechanism driving PKM2 up-regulation in HCC. By in silico analysis with the algorithm Target Scan 5.2, we studied the 3UTR of PKM2 and found that miR-122 could potentially interact with the 3UTR of PKM2. MiR-122 theoretically could interact with the 3UTR of both PKM1 and PKM2. However, as HCC cells expressed high level of PKM2 but not PKM1 (Fig. 1A) , the functional effects driven by miR-122 should mainly be contributed by PKM2. To validate the interaction between miR-122 and PKM2, we cloned the wild-type (WT) and mutant (Mut) 3UTRs of PKM2 into the pmirGLO luciferase reporter vector (Fig. 4A) . We also cloned the sensor sequence which was completely complementary to miR-122 as a positive control. Luciferase reporter assay showed that miR-122 suppressed the WT 3UTR and effect was reduced in the Mut 3UTR of PKM2 (Fig. 4B) . To assess whether PKM2 expression was affected by miR-122, we transiently transfected miR-122 precursors into HCC cell lines and found that miR-122 suppressed the protein expression of PKM2 but not PKL, the predominant form in normal livers (Fig. 4C) . Interestingly, miR-122 precursors did not affect the phosphorylation of PKM2 at Tyrosine 105, indicating that miR-122 only regulated the expression but not the activity of PKM2 (S4 Fig.) . Importantly, linear regression model showed that miR-122 expression inversely correlated with PKM2 expression in our cohort of HCC and NT liver tissues (Fig. 4D) .
MiR-122 in human HCCs
To further interrogate the roles of miR-122 in human HCC, we looked into our previous miRNA array study which compared the expression of.667 microRNA species in tumor and NT specimens in 20 HCC patients. Consistent with other . Data were retrieved from low density microarray in which expressions of 667 miRNA species were compared between NT, HCC, and VM. B, *P,0.05, ** P,0.01, *** P,0.001, Student's t test (n §3). E, *P,0.05, **P,0.01, Wilcoxon signed rank test. reports, miR-122 was one of the most abundantly expressed miRNAs in the human liver (Fig. 4E) . The abundance of miR-122 in the human liver implies that miR-122 might play an important role in human liver. Moreover, we found that miR-122 was significantly under-expressed in human HCC tissues as compared to NT livers and was further under-expressed in venous metastases (VM) (Fig. 4F) . As we have shown earlier in this study that PKM2 promoted the Warburg effect in HCC, we studied the metabolic roles of miR-122 in HCC cell lines. We generated MHCC-97L and SMMC-7721 cells that stably expressed miR-122 (Fig. 5A ) and found that miR-122 profoundly reduced the PKM2 expression (S5 Fig.) lactate accumulation (Fig. 5B ) and glucose uptake rate (Fig. 5C-E) in MHCC-97L cells. Conversely, inhibition of miR-122 in HCC cell line with high expression of miR-122, PLC/PRF/5, by LNA enhanced glucose uptake rate (Fig. 5F ). More importantly, re-expression of miR-122 in MHCC-97L significantly impeded tumor growth and attenuated lung metastasis (Fig. 5G-H ).
Discussion
Our study has provided evidence that PKM2 was over-expressed in human HCCs. Our finding further supports the general observation that PKM2 is the isoform particularly expressed in tumors. Furthermore, we found that PKM2 overexpression was closely associated with aggressive pathological HCC features and poor survival rates. Our findings, together with others, suggest that PKM2 overexpression confers advantage to cancer cell growth. Conversely, a number of studies have shown that reduction of PKM2 enzymatic activity promotes tumor growth by influencing the generation of anabolic intermediates [14] [15] [16] . Phosphotyrosine phosphorylation, reactive oxygen species, and lysine acetylation have been shown to modulate the activity of PKM2 [14] [15] [16] . Small-molecule activators of PKM2 also suppressed tumor growth [17] . Although it remains intriguing why a lowered PKM2 activity would benefit tumor growth while PKM2 is the predominant form found in cancers, all these studies have clearly indicated that deregulation of PKM2 is pivotal to tumor growth. Of note, these studies only compared the oncogenic activities of PKM2 and PKM1 as most cancers do not express PKL/R isoforms. In the context of the liver, PKL is the most dominant isoform. Our data clearly showed that knockdown of PKM2 but not PKL in HCC cells suppressed HCC proliferation. This finding seems to be in contradiction with a recent publication showing that mice with specific knockout of PKM2 are prone to breast cancer development [18] . The discrepancy between this study and others can be attributed by the compensatory effect of PKL in HCC and different animal experimental models. Therefore, how the activities of PKL, PKM1, and PKM2 are maintained along hepatocarcinogenesis to maximize HCC growth will be the next important question to be addressed in the future. Although we believe that specific knockdown or inhibition of PKM1 would only have minimal effect in HCC growth due to the abundance of other pyruvate kinase isoforms in HCC, the roles of PKM1 in HCC merit further investigation. glucose metabolism have not been clearly elucidated. Our current study has unequivocally revealed the precise mechanisms by which miR-122 regulated the PK isoform switching in HCC, the clinical relevance of PKM2, and the clinical association of PKM2 and miR-122.
At the time of manuscript submission, we noticed a report by Liu et al. that shares similar findings with our current study [29] . Although Liu et al. started from the angle of miR-122 and discovered PKM2 as its target while our current study started from the angle of different PK isoforms and discovered miR-122 as the regulator of PKM2, two studies converged to an important conclusion. While our data echo Liu et al.'s in vitro findings, we additionally demonstrated that PKM2 and miR-122 were critical to HCC growth in vivo using both subcutaneous and orthotopic implantation models. Furthermore, we showed that PKL was the dominant isoform in normal liver while PKM2 was overexpressed in HCC. Our in vivo data and findings on different PK isoforms will be particularly important to preclinical studies which involve the design of therapeutic strategies that specifically target PKM2. The clinicopathological findings from the two studies are consistent although different primers were employed, reinforcing the important diagnostic and prognostic roles of PKM2 in HCC. Intriguingly, we showed that overexpression was associated with higher recurrence rate. Of note, in addition to the effect of PKM2 in lactate production that both studies reported, we showed that knockdown of PKM2 suppressed the glucose uptake rate and increased the oxidative stress in HCC cells. This information is especially important to the understanding of the complex metabolic machinery of HCC. Our data suggested that PKM2 may channel glucose intermediates (glucose-6-phosphate) to the pentose phosphate shunt which produces NADPH to reduce the level of ROS in the cells, therefore further conferring a growth advantage to HCC cells. Taken together, Liu et al.'s and our current studies contain complementary information supporting the important metabolic roles of miR-122/PKM2 in HCC development. 
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